Piramal Pharma's Loss Masks Turnaround Signs After 'Transitional' Year

MUMBAI, India – April 28, 2026 – Piramal Pharma Limited reported a challenging fiscal year 2026, swinging to a consolidated net loss of ₹326 Crores from a profit of ₹91 Crores the previous year. The loss was driven primarily by a significant one-time impairment charge, overshadowing signs of a strategic rebound and strong performance in key business units. Company leadership has framed the period as a "transitional year," expressing confidence in a return to accelerated growth for FY27.

The Mumbai-based global pharmaceutical company saw its consolidated revenue from operations dip by 3% year-over-year to ₹8,869 Crores. Earnings before interest, taxes, depreciation, and amortization (EBITDA) fell 28% to ₹1,135 Crores, compressing the EBITDA margin to 13% from 17% in FY25.

A Year of Contrasts and Write-Downs

The central factor pulling the company into the red was an exceptional impairment loss totaling ₹196 Crores for the full year, with ₹176 Crores of that recognized in the fourth quarter. This charge was related to "intangible assets under development." According to the company, a reassessment of market conditions and updated commercial viability estimates led management to conclude that the future economic benefits from these specific assets were no longer adequate to justify further investment. Consequently, their carrying value was written down entirely.

This strategic write-down, while significantly impacting the bottom line, appears to be a move to clean the balance sheet of underperforming developmental projects and refocus capital on more promising ventures. Despite the drop in revenue and profitability, the company managed to maintain its net debt at the same level as the previous fiscal year, indicating disciplined financial management amidst the headwinds.

The CDMO Business: A Tale of Two Halves

Piramal's largest segment, the Contract Development and Manufacturing Organization (CDMO) business, which serves other pharmaceutical companies, faced significant challenges, with revenue declining 10% year-over-year to ₹4,915 Crores. The company attributed this decline to two main factors: inventory destocking by clients and a slowdown in early-stage order inflows during the first half of the fiscal year, a period marked by inconsistent recovery in US biopharma funding.

However, the narrative for the CDMO business shifted dramatically in the second half of FY26. Chairperson Nandini Piramal noted a powerful turnaround, stating, "The meaningful recovery in biopharma funding seen from Sep'25, is translating into good RFP momentum and healthy pick up in order inflows in our CDMO business." This was supported by industry data showing a 75% year-over-year increase in US biopharma funding in the second half of the fiscal year.

The company is also investing heavily to capture this renewed momentum. A capital expenditure of US$90 million is on track to expand sterile injectable and payload-linker capacities at its key US sites in Lexington, Kentucky, and Riverview, Michigan. These investments in high-demand, differentiated capabilities, coupled with a record 209 customer site audits and a strong Net Promoter Score of 60, signal strengthening operational capabilities and customer engagement.

Strategic Bets in Generics and Consumer Health

While the CDMO segment navigated a difficult year, Piramal's other divisions provided stability and strong growth. The Complex Hospital Generics (CHG) business posted a 3% revenue increase to ₹2,703 Crores. A key driver for its future growth is the recently completed acquisition of Kenalog®, a niche brand with a complex manufacturing process. The deal, valued at up to US$100 million including contingent payments, broadens the CHG portfolio and expands its presence across the US, Europe, and Asia Pacific with minimal incremental cost. The company also maintained its market leadership in key hospital products, holding a 47% market share in inhalation anesthesia and the #1 rank in the US for intrathecal Baclofen.

The standout performer for FY26 was the Piramal Consumer Healthcare (PCH) division, which delivered robust 17% year-over-year growth, reaching revenues of ₹1,274 Crores. This growth was fueled by its "Power Brands" like Little's and Lacto Calamine, which grew by 24%. Most impressively, the division's e-commerce sales skyrocketed by 48%, now accounting for 27% of its total sales. This reflects a successful strategy focused on premiumization and a pivot towards high-margin digital channels, including quick commerce.

Charting a Course for Growth in FY27

Despite the headline loss, Piramal Pharma's leadership projects a clear path back to profitability. The company exited FY26 with positive momentum across all three of its core businesses, setting the stage for what it expects to be a year of significant recovery.

"FY26 was a transitional year, shaped by external disruptions and certain business-specific factors," said Nandini Piramal in the company's earnings announcement. "Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses... Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT."

The strategy for the upcoming year hinges on capitalizing on the recovering CDMO market, integrating the Kenalog® acquisition to bolster the hospital generics business, and continuing the powerful growth trajectory of the consumer healthcare division. With major capital investments beginning to bear fruit and a cleaner balance sheet after the impairment, the company is positioning itself to leverage these distinct but complementary growth engines for a much stronger performance in the year ahead.